Download App
Current Complaints | Help Center| Subscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Tonira Pharma Ltd (530155)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530155 NSE: Pharmaceuticals & Drugs | Small Cap | Tonira Pharma Share Price

BSE Share Price
Not Listed

Tonira Pharma Ltd (530155)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530155 NSE: Pharmaceuticals & Drugs | Small Cap | Tonira Pharma Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹16 Cr.
Current Price
₹0
52-Week Low / High
₹19 / 20
TTM EPS
₹-2.6
TTM Sales
₹30.2 Cr.
Book Value per Share
₹15.3
P/E Ratio
0.00
Industry PE
53.6
Price to Book (P/B)
1.29
Price to Sales (P/S)
0.52
EV/EBITDA
12.53
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
-15.74%
Return on Capital Employed (ROCE)
1.98%
Return on Assets (ROA)
-3.87%
Operating Profit Margin
8.1%
Net Profit Margin
-6.89%
Gross Profit Margin
2.9%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-18.12%
Operating Profit Growth (1 Year)
-
-62.18%
Net Profit Growth (1 Year)
-
-303.92%
Asset Quality
Promoter Holding
37.27%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹4 Cr.
Equity
₹7.9 Cr.
Face Value
₹10
All Time Low / High
₹0.80 / 50.30

Tonira Pharma stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation ⓘ

Mar'02Mar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11TTM
ROCE % ⓘ13.2%18.1%5.9%10.8%11%11.4%-17.3%7.8%9.9%2%-

Growth Parameters ⓘ
Sales ⓘ19.42426.222.529.436.832.641.336.930.233
Sales YoY Gr.-23.3%9.1%-13.8%30.3%25.2%-11.5%26.8%-10.7%-18.1%-
Adj EPS ⓘ2.43.40.11.82.32.2-4.32.50.8-3.8-4.2
YoY Gr.-44.5%-96.5%1425%25.1%-6.1%-300.5%NA-66.9%-565.9%-
BVPS (₹) ⓘ15.416.517.5212324.717.516.418.115.412.5
Adj Net
Profit ⓘ		1.92.70.11.51.81.7-3.420.7-3-3
Cash Flow from Ops. ⓘ2.84.52.73.7-0.65.1-7.13.87.5-0.9-
Debt/CF from Ops. ⓘ2.10.82.54.2-37.73.9-4.17.14.2-39.4-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ5%0.6%-2.5%-18.1%
Adj EPS ⓘ-205.4%-210.8%NA-565.9%
BVPSⓘ0%-7.7%-4%-14.5%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'02Mar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11TTM
Return on
Equity % ⓘ		16.2210.79.410.38.9-2014.44.8-22.8-30.2
Op. Profit
Mgn % ⓘ		6.77.35.317.421.819.3-3.123.917.28.10.7
Net Profit
Mgn % ⓘ		9.711.40.46.46.24.6-10.54.81.8-10.1-10
Debt to
Equity ⓘ		0.50.30.50.91.212.12.12.23-
Working Cap
Days ⓘ		219182157186185189240211248314269
Cash Conv.
Cycle ⓘ		12280649397100128100131187203

Valuation of Tonira Pharma - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'10Mar'11
Sales36.8630.18
Operating Expenses ⓘ + 30.5527.80
Manufacturing Costs3.964.77
Material Costs18.1915.63
Employee Cost 4.524.33
Other Costs ⓘ 3.883.06
Operating Profit ⓘ 6.322.39
Operating Profit Margin (%) 17.1%7.9%
Other Income ⓘ + 0.751.62
Exceptional Items ⓘ 00
Interest ⓘ 2.883.14
Depreciation ⓘ 2.843.07
Profit Before Tax ⓘ 1.35-2.20
Tax ⓘ 0.33-0.12
Profit After Tax 1.02-2.08
PAT Margin (%) 2.8%-6.9%
Adjusted EPS (₹)1.3-2.6
Dividend Payout Ratio (%)0%0%
PARTICULARSMar'10Mar'11

Equity and Liabilities

Shareholders Fund + 14.2612.18
Share Capital ⓘ 7.947.94
Reserves ⓘ 6.314.23
Debt +31.2936.73
Long Term Debt31.2936.73
Short Term Debt00
Minority Interest00
Trade Payables6.525.13
Others Liabilities ⓘ 0.800.62
Total Liabilities ⓘ 52.8754.66

Fixed Assets

Net Fixed Assets ⓘ +24.7123.56
Gross Block45.4147.03
Accumulated Depreciation20.7023.47
CWIP ⓘ 0.541.21
Investments ⓘ 0.040.04
Inventories11.7315.56
Trade Receivables6.333.81
Cash Equivalents 3.082.22
Others Assets ⓘ 6.438.26
Total Assets ⓘ 52.8754.66
PARTICULARSMar'10Mar'11
Cash Flow From Operating Activity ⓘ + 6.15-0.93
PBT ⓘ 1.34-2.20
Adjustment ⓘ 5.154.97
Changes in Working Capital ⓘ 0.11-3.46
Tax Paid ⓘ -0.42-0.19
Cash Flow From Investing Activity ⓘ + -3.72-2.63
Capex -3.72-2.63
Net Investments 00
Others ⓘ -00
Cash Flow From Financing Activity ⓘ + 0.092.71
Net Proceeds from Shares ⓘ 00
Net Proceeds from Borrowing ⓘ 2.874.04
Interest Paid ⓘ -2.68-1.33
Dividend Paid ⓘ 00
Others ⓘ -0.110
Net Cash Flow ⓘ 2.52-0.86
PARTICULARSMar'10Mar'11
Ratios
ROE (%)7.17-15.74
ROCE (%)9.281.98
Asset Turnover Ratio0.70.57
PAT to CFO Conversion(x)6.03N/A
Working Capital Days
Receivable Days62.4060.90
Inventory Days115.60163.80
Payable Days71.7071.40

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Tonira Pharma Ltd FAQs

The current trading price of Tonira Pharma on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Tonira Pharma stood at ₹15.69 Cr

The latest P/E ratio of Tonira Pharma as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Tonira Pharma as of 31-Dec-1969 is 1.58.

The 52-week high of Tonira Pharma is ₹19.90 and the 52-week low is ₹19.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Tonira Pharma is ₹33.49 ( Cr.) .

Data is not available for this company.

No data found

No data found

About Tonira Pharma Ltd

Tonira Pharma incorporated, in 1992, is engaged in the business of manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and intermediates.

The company's manufacturing locations at Nandesari and Ankleshwar are inspected and approved by PMDA Japan. With the USFDA approval of the Nandesari plant and PMDA Japan approvals of both the plants, the company will now have access to regulated markets for its APIs.

Tonira operates a state-of-the-art R&D Center at Nandesari, Vadodara District in Gujarat. The centre is continuously developing newer value-added APIs through innovative and cost-effective processes.

Tonira undertakes contract synthesis both on exclusive and non-exclusive basis.  The company has the capability to provide contract research and manufacturing services to its customers.

Products

APIs- Under this, the company manufactures Atenolo, Aceclofenac, Benzbromarone, Benzarone, Desloratadine, Ebastine, Famotidine, Glimepiride, Loratadine, Meloxicam, Mosapride Citrate, Nifedipine, Ofloxacin, Quetiapine Fumarate, Sodium Alendronate, Tramadol HCI, Tamsulosin HCI and Zolpidem Tartrate.

Recognitions/Achievements

  • Tonira Pharma has received WHO-GMP approval for its manufacturing facility.
  • The company is recipient of export award for two successive years from DGFT.
  • Its R&D centre is recognized by Department of Science & Technology, Government of India.
  • The company has been recognised as an Export House by Government of India.
You have 39 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now